𝐅𝐫𝐨𝐦 𝐉𝐚𝐩𝐚𝐧: Takeda's CEO Christophe Weber talks about the company's Japanese roots, but global transformation - plus, five key pipeline assets. $TAK Full video: biotechtv.com/post/takeda-ch…

Glad to see Rusfertide, partnership drug of Protagonist Therapeutics with Takeda on that list of five key pipeline assets. Cheers!

In BioCentury’s latest Clinical Report: New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data; CRISPR, RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte buff.ly/4fTSr8y

Looking forward to ASH 2024!

Everybody needs to read this article. Very facts based, in my opinion.

On Feb. 6 at 10:30am ET, KOLs Andrew Andrew Kuykendall MD and Joseph Michael Scandura, MD, PhD, will discuss the unmet medical need and current treatment landscape for patients with polycythemia vera (PV). Register for the in-person and virtual event here: bit.ly/40tSC47

One year ago today, the NEJM published pivotal data from the Phase 2b FRONTIER 1 trial, evaluating an oral peptide designed to selectively block IL23R in adults living with moderate-to-severe plaque #psoriasis (PsO). See a video summary of the findings:

Whether you joined us in-person or virtually, we’d like to thank everyone who took part in our investor event to learn about Protagonist’s ongoing research to address unmet medical needs for polycythemia vera (PV) patients. (1/2)

Many thanks to Dr. Andrew Andrew Kuykendall MD from Moffitt Cancer Center and Dr. Joseph Scandura from Weill Cornell Medicine for sharing your expertise and leading an insightful discussion on current and future treatment options for PV. (2/2)

On Intl. Day of Women & Girls in Science we celebrate the women in STEM inspiring the next generation of innovators! We also give a shoutout of appreciation to the impactful Protagonist team members, collaborators, and researchers supporting our mission to improve patient lives.

Rare disease, but of paramount importance and attention in the $PTGX universe. Let’s try to make a difference !

The Protagonist Therapeutics team shared highly positive topline results today from the VERIFY Ph 3 rusfertide study in polycythemia vera. We sincerely thank all the participants, and look forward to working with our partners Takeda on NDA submission. feeds.issuerdirect.com/news-release.h…

Great results. Icotrokinra continues to establish itself as potentially the best oral psoriasis agent and set a new standard of treatment in psoriasis. Congrats Johnson & Johnson Innovation and Protagonist Therapeutics

Only one way to sum it up; Cheers! Congrats teams J&J Innovative Medicine and Protagonist Therapeutics. Can’t wait to see this translating into real benefit to patients.

Congrats Team Protagonist Therapeutics. We're truly honored to be named one of Fast Company's most innovative companies of 2025. A new beginning. Cheers!

#ASCO2025 was truly enjoyable for the Protagonist Therapeutics team; hopefully we will make a big difference in the lives of #polycythemia Vera community with #Rusfertide.

Great coverage of rusfertide in today’s The Wall Street Journal. Developing rusfertide has been a long, passionate journey for Protagonist Therapeutics. Thanks to team Protagonist for their tireless dedication, and to @Takeda for their excellent partnership.   wsj.com/health/healthc…

Back to basics with solid ‘oral peptide’ differentiation in obesity, and with two NDA filings sometime in 2025 in rear view mirror - Icotrokinra with JNJ 🎗️ and Rusfertide with Takeda Oncology. Feels like a rejuvenating reincarnation!

A landmark moment for #PTGX: the NDA for oral #icotrokinra has been submitted to the FDA. This is the first NDA resulting from our peptide discovery & development platform in collab with our partners at Johnson & Johnson. Congrats & thanks to everyone on the PTGX and J&J teams. Cheers!